Modified-Release Orlistat-Acarbose Composition for GI Side Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity, overweight, type 2-diabetes, and metabolic disorders such as nonalcoholic steatohepatitis (NASH) are limited in efficacy and often associated with significant side effects, necessitating a safer and more effective pharmaceutical composition.
Innovation Solution
A modified release oral pharmaceutical composition comprising orlistat and acarbose, designed to release these drugs in specific parts of the gastrointestinal tract at varying rates to optimize enzyme inhibition and nutrient-induced satiety mechanisms, thereby reducing side effects and enhancing treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orlistat and acarbose are administered simultaneously in conventional formulations, then enzyme inhibition and nutrient-induced satiety mechanisms are activated, but gastrointestinal side effects increase and tolerability decreases
Solution Approach 1:
The patent divides the single-dose administration into multiple release phases using a multi-layered tablet structure. The first layer releases orlistat in the stomach to inhibit lipase, while the second layer releases acarbose in the small intestine to inhibit carbohydrate-digesting enzymes. This temporal and spatial segmentation allows each drug to act at its optimal location without compounding gastrointestinal side effects from simultaneous release of both agents.
Solution Approach 2:
The patent applies different release characteristics to different regions of the gastrointestinal tract. Orlistat is designed to release in the stomach where lipase activity is highest, while acarbose is designed to release in the small intestine where carbohydrate digestion occurs. This localized delivery optimizes therapeutic effect while minimizing systemic and gastrointestinal side effects by matching drug release to physiological enzyme distribution.
2Speed
If conventional rapid-release formulations are used, then immediate enzyme inhibition occurs, but drug degradation in acidic stomach environment reduces efficacy
Solution Approach 1:
The patent incorporates enteric coating on the acarbose layer, which is designed to resist dissolution in the acidic stomach environment and only release the drug in the neutral pH of the small intestine. This preliminary protection ensures that acarbose reaches its target site intact, preventing premature degradation while maintaining rapid onset of action once released in the appropriate environment.
Solution Approach 2:
The patent exploits the pH gradient along the gastrointestinal tract to control drug release. The enteric coating is formulated to remain stable at gastric pH (acidic) but dissolve at intestinal pH (neutral). This parameter-based control allows the drug to survive the harsh stomach environment and release at the optimal location, balancing stability during transit with rapid action upon arrival at the target site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves improved weight management and glucose control with reduced side effects by targeting the gastrointestinal brake, providing a synergistic effect with lower doses of orlistat and acarbose compared to conventional forms.
Implementation Method 1
utilizing enteric coating principles to minimize pH-dependent degradation
Data Source
AI summary
The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns:a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose,b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose,c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, andd) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.